iCAD announces new credit facility with Bridge Bank, increasing operational flexibility

iCAD announces new credit facility with Bridge Bank, increasing operational flexibility

Press releases may be edited for formatting or style | March 31, 2020 Business Affairs
NASHUA, N.H., March 31, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it has entered into a credit facility with Bridge Bank, a division of Western Alliance Bank, effective March 30, 2020.

The new credit facility consists of a $7 million term loan and a $5 million revolving line of credit. The four-year term loan will be interest-only for the first 18 months, which could be extended by an additional six months, if certain conditions are met. The line of credit has a two-year term and may be repaid and reborrowed at any time until its maturity date.

"We are pleased to obtain this new financing from Bridge Bank during this period of unprecedented economic impact from the global coronavirus pandemic," said Michael Klein, Chairman and CEO of iCAD. "This new credit facility, and support from Bridge Bank, strengthens our balance sheet and provides us with additional operating flexibility."

INNOVATION IN RADIATION PROTECTION
YOUR SAFETY IS OUR CONCERN™

Through our steadfast commitment to product innovation, we have developed MagnaGuard™ a revolutionary magnetic closure system that eliminates the need for Velcro and allows you to properly clean & disinfect your Protective X-ray Apparel. (800) 353-4350

"The novel coronavirus (COVID-19) is impacting the healthcare system as a whole. Although we do not provide guidance to investors relating to results of operations, we expect that our results will be impacted as shipping, logistics, installation and training have been delayed and ordering patterns disrupted. We began to see this emerge in March and anticipate that it will continue through Q2.

During these uncertain times we remain very focused on disciplined execution of the highest return opportunities," Mr. Klein continued. "This environment allows us to prove the unique value of our technologies. This includes one-day radiation therapy cancer treatment and AI-based solutions that personalize breast cancer screening based on individual patient risk characteristics."

Reference:
1. Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.

ProFound AI™ is a high-performing workflow solution for 2D and 3D mammography, or digital breast tomosynthesis (DBT), featuring the latest in deep-learning artificial intelligence. In 2018, ProFound AI for Digital Breast Tomosynthesis (DBT) became the first artificial intelligence (AI) software for DBT to be FDA-cleared; it was also CE marked and Health Canada licensed that same year. It offers clinically proven time-savings benefits to radiologists, including a reduction of reading time by 52.7 percent, thereby halving the amount of time it takes radiologists to read 3D mammography datasets. Additionally, ProFound AI for DBT improved radiologist sensitivity by 8 percent and reduced unnecessary patient recall rates by 7.2 percent.1

You Must Be Logged In To Post A Comment